US Pharmaceutical Market Outlook 2011-2021
Do you want to know the effects of the Obama government's legislation for US healthcare? Insurance coverage will be extended, expanding the pharma market. But at what price to the pharmaceutical industry in rebates and other costs? Will the healthcare reforms underwrite another decade of growth in the US pharma market, or has it reached its limits?
US Pharmaceutical Market Outlook 2011-2021 answers those questions with a deep, wide-ranging survey of the market. Our report analyses the leading therapeutic categories in the US market. We assess which areas have the strongest potential for growth and the most-promising R&D pipelines. You will also find out which areas are most threatened with contraction as patent expiries occur. Order today, staying ahead.
We provide forecasts and discussions for the top drugs in the US market. We profile the US market's leading players, with analyses of their growth strategies. Our report covers their plans to expand and diversify their portfolios, restructure their operations and consolidate positions in emerging markets. We provide revenue forecasts for the top companies in the US market and worldwide, putting the US market in context.
Our new report also provides analyses of the US generic drug market and the US OTC pharma market, studying the market drivers and restraints. We provide forecasts for those markets, and for leading companies in those rising sectors.
This report contains interviews with experts on prospects for the US market this decade, discussing matters such as:
Analysis and expert opinion to aid your work - so you won't be left behind
US Pharmaceutical Market Outlook 2011-2021 critically examines the world's most important pharma market. You will find sales forecasts, market share analyses, discussions of products and analyses of commercial drivers and restraints.
We include 120 tables and figures and two expert interviews (shown in the accompanying lists). You can stay ahead by ordering our report today, benefiting your analyses and commercial ideas.
US Pharmaceutical Market Outlook 2011-2021 shows you revenue trends, opportunities and challenges
Our report gives you the following advantages:
US Pharmaceutical Market Outlook 2011-2021 answers those questions with a deep, wide-ranging survey of the market. Our report analyses the leading therapeutic categories in the US market. We assess which areas have the strongest potential for growth and the most-promising R&D pipelines. You will also find out which areas are most threatened with contraction as patent expiries occur. Order today, staying ahead.
We provide forecasts and discussions for the top drugs in the US market. We profile the US market's leading players, with analyses of their growth strategies. Our report covers their plans to expand and diversify their portfolios, restructure their operations and consolidate positions in emerging markets. We provide revenue forecasts for the top companies in the US market and worldwide, putting the US market in context.
Our new report also provides analyses of the US generic drug market and the US OTC pharma market, studying the market drivers and restraints. We provide forecasts for those markets, and for leading companies in those rising sectors.
This report contains interviews with experts on prospects for the US market this decade, discussing matters such as:
- FDA funding and regulatory transparency
- The biosimilars market in light of the 2010 healthcare reforms
- The erosion of industry leadership to Europe
- The pressure on pricing within the US health insurance industry
- The legal and political complexities of the US pharma market this decade.
Analysis and expert opinion to aid your work - so you won't be left behind
US Pharmaceutical Market Outlook 2011-2021 critically examines the world's most important pharma market. You will find sales forecasts, market share analyses, discussions of products and analyses of commercial drivers and restraints.
We include 120 tables and figures and two expert interviews (shown in the accompanying lists). You can stay ahead by ordering our report today, benefiting your analyses and commercial ideas.
US Pharmaceutical Market Outlook 2011-2021 shows you revenue trends, opportunities and challenges
Our report gives you the following advantages:
- You will receive a detailed analysis of prospects for the US market's growth from 2011 to 2021, including forecasts for main therapeutic categories, and those for the generic and OTC sectors
- You will find out how companies are performing in the US market, with forecasts and discussions for the leading companies overall, and for leading generics and OTC companies
- You will learn prospects for the leading products in the US pharma market, with US revenue forecasts for top brands
- You will discover the legal, regulatory and economic drivers and restraints operating in the US pharma market, especially implications of the 2010 healthcare reforms
- You will identify the key industry trends in this market, seeing opportunities and market requirements
- You will read expert opinion from our survey, including full interview transcripts.
1. EXECUTIVE SUMMARY
1.1 US Pharmaceutical Market Summary
1.2 Contents Overview
1.3 Methods of Analysis
2. THE US PHARMA MARKET IN 2010
2.1 The 2010 Healthcare Reforms
2.1.1 Existing Healthcare Coverage
2.1.1.1 Medicare
2.1.1.2 Medicaid
2.1.1.3 Other Public Programmes
2.1.1.4 Employer Funded Healthcare
2.1.1.5 Private Healthcare Insurance
2.1.2 The Cost of US Healthcare
2.1.3 The Provisions of the 2010 Healthcare Reforms
2.1.4 Opposition to Reforms
2.1.5 Benefits and Costs to the Pharmaceutical Industry of the 2010 Health Care Reforms
2.2 Other Influences on the US Market in 2010
2.2.1 Pricing Policy
2.2.2 The End of the Blockbuster Model?
2.2.3 The Regulatory Environment
2.2.3.1 FDA Stringency
2.2.3.2 Lack of Transparency
2.2.3.3 Overstretch
3. OVERVIEW OF US MARKET, 2011-2021
3.1 US Market Revenues Can Rise Significantly
3.1.1 The US and China
3.2 CNS Products Are The Largest Market Sector in 2010
3.2.1 Forecast for CNS Products
3.3 Cardiovascular Products
3.3.1 Forecast for Cardiovascular Products
3.3 Oncology Products
3.3.1 Forecast for Oncology Products
3.4 Anti-infective Products
3.4.1 Forecast for Anti-infective Products
3.5 Alimentary/Metabolism Products
3.5.1 Forecast for Metabolism Products
3.6 Other Products
4. TOP PRODUCTS IN THE US MARKET
4.1 Lipitor (Pfizer)
4.2 Plavix (Bristol-Myers Squibb)
4.3 Seretide (GlaxoSmithKline)
4.4 Seroquel (AstraZeneca)
4.5 Remicade (Johnson & Johnson)
5. TOP COMPANIES IN THE US MARKET
5.1 Pfizer
5.1.1 Pfizer's Growth Strategy
5.1.1.1 New Markets
5.1.1.2 Portfolio Management
5.1.1.3 Diversification and Restructuring
5.1.2 Forecast for Pfizer
5.2 Roche
5.2.1 Roche's Growth Strategy
5.2.1.1 New Markets
5.2.1.2 Portfolio Management
5.2.1.3 Diversification and Restructuring
5.2.2 Forecast for Roche
5.3 AstraZeneca
5.3.1 AstraZeneca's Growth Strategy
5.3.1.1 New Markets
5.3.1.2 Portfolio Management
5.3.1.3 Diversification and Restructuring
5.3.2 Forecast for AstraZeneca
5.4 Merck & Co.
5.4.1 Merck & Co's Growth Strategy
5.4.1.1 New Markets
5.4.1.2 Portfolio Management
5.4.1.3 Diversification and Restructuring
5.4.2 Forecast for Merck & Co.
5.5 Novartis
5.5.1 Novartis' Growth Strategy
5.5.1.1 New Markets
5.5.1.2 Portfolio Management
5.5.1.3 Diversification and Restructuring
5.5.2 Forecast for Novartis
6. US GENERICS MARKET 2011-2021
6.1 The US Generics Market Achieved 2009 Revenues of $35.6bn
6.2 Forecast for the US Generics Market, 2010-2021
6.2.1 US and China: Generics
6.3 Analysis of the US Generics Market
6.3.1 Pro-Generic Government Policies
6.3.2 Many More Blockbuster Products Will Become Susceptible to Generic Competition
6.3.3 Pricing Pressure and Regulation
6.3.4 The ANDA Backlog
6.4 Key Players in the US Generics Market
6.4.1Teva
6.4.2 Mylan
6.4.3 Sandoz
6.4.4 Hospira
6.4.5 Watson
6.5 Biosimilars
7. US OTC MARKET 2011-2021
7.1 The US OTC Market Achieved 2009 Revenues of $19.4bn
7.2 Forecast for the US OTC Market
7.3 Analysis of the US OTC Market
7.3.1 OTC Products Have Several Advantages
7.3.2 Rx-to-OTC Switching: The OTC Product Pipeline
7.3.3 Difficulties with OTC Switching
7.3.4 Sales Channels
7.4 Leading Companies in the US OTC Market
7.4.1 Johnson & Johnson
7.4.2 Procter & Gamble
7.4.3 Bayer
7.4.4 Novartis
7.4.5 Perrigo Company
8. EXPERT OPINIONS
8.1 Interview with Robert J. Easton
8.1.1 Pros and Cons of the 2010 Health Care Reform Bills
8.1.2 The Reform of Pricing
8.1.3 Different Strategies in the Industry
8.1.4 On Emerging Markets and the Loss of American Industry Leadership
8.2 Interview with Steven A. Grossman
8.2.1 On The Prospects for Health Care Reform
8.2.2 Opposition to the Reforms
8.2.3 Effects of the Bill
8.2.4 On Biosimilars Prospects
8.2.5 On FDA Regulation
8.2.6 On the Legal Challenge to the Industry
8.2.7 On FDA Funding
9. SWOT ANALYSIS OF US MARKET: CONCLUSIONS
9.1 Strengths of the US Market
9.1.1 The US Pharma Market is the Largest in the World
9.1.2 The 2010 Health Care Reforms Will Increase Coverage
9.1.3 Unmet Market Needs
9.2 Weaknesses of the US Market
9.2.1 The US Market Has Low Growth Rates
9.2.2 Margins Can Only Get Smaller
9.2.3 US Leadership and Centrality Have Decreased
9.3 Opportunities in the US Market
9.3.1 Biologicals and Biosimilars Will Grow
9.3.2 Good Prospects in Oncology
9.3.3 Opportunities in Generics and OTC Markets
9.4 Threats to the US Market
9.4.1 Opposition to Reforms
9.4.2 FDA Shortcomings
9.4.3 The Competitive Threat of China
9.5 Conclusions
1.1 US Pharmaceutical Market Summary
1.2 Contents Overview
1.3 Methods of Analysis
2. THE US PHARMA MARKET IN 2010
2.1 The 2010 Healthcare Reforms
2.1.1 Existing Healthcare Coverage
2.1.1.1 Medicare
2.1.1.2 Medicaid
2.1.1.3 Other Public Programmes
2.1.1.4 Employer Funded Healthcare
2.1.1.5 Private Healthcare Insurance
2.1.2 The Cost of US Healthcare
2.1.3 The Provisions of the 2010 Healthcare Reforms
2.1.4 Opposition to Reforms
2.1.5 Benefits and Costs to the Pharmaceutical Industry of the 2010 Health Care Reforms
2.2 Other Influences on the US Market in 2010
2.2.1 Pricing Policy
2.2.2 The End of the Blockbuster Model?
2.2.3 The Regulatory Environment
2.2.3.1 FDA Stringency
2.2.3.2 Lack of Transparency
2.2.3.3 Overstretch
3. OVERVIEW OF US MARKET, 2011-2021
3.1 US Market Revenues Can Rise Significantly
3.1.1 The US and China
3.2 CNS Products Are The Largest Market Sector in 2010
3.2.1 Forecast for CNS Products
3.3 Cardiovascular Products
3.3.1 Forecast for Cardiovascular Products
3.3 Oncology Products
3.3.1 Forecast for Oncology Products
3.4 Anti-infective Products
3.4.1 Forecast for Anti-infective Products
3.5 Alimentary/Metabolism Products
3.5.1 Forecast for Metabolism Products
3.6 Other Products
4. TOP PRODUCTS IN THE US MARKET
4.1 Lipitor (Pfizer)
4.2 Plavix (Bristol-Myers Squibb)
4.3 Seretide (GlaxoSmithKline)
4.4 Seroquel (AstraZeneca)
4.5 Remicade (Johnson & Johnson)
5. TOP COMPANIES IN THE US MARKET
5.1 Pfizer
5.1.1 Pfizer's Growth Strategy
5.1.1.1 New Markets
5.1.1.2 Portfolio Management
5.1.1.3 Diversification and Restructuring
5.1.2 Forecast for Pfizer
5.2 Roche
5.2.1 Roche's Growth Strategy
5.2.1.1 New Markets
5.2.1.2 Portfolio Management
5.2.1.3 Diversification and Restructuring
5.2.2 Forecast for Roche
5.3 AstraZeneca
5.3.1 AstraZeneca's Growth Strategy
5.3.1.1 New Markets
5.3.1.2 Portfolio Management
5.3.1.3 Diversification and Restructuring
5.3.2 Forecast for AstraZeneca
5.4 Merck & Co.
5.4.1 Merck & Co's Growth Strategy
5.4.1.1 New Markets
5.4.1.2 Portfolio Management
5.4.1.3 Diversification and Restructuring
5.4.2 Forecast for Merck & Co.
5.5 Novartis
5.5.1 Novartis' Growth Strategy
5.5.1.1 New Markets
5.5.1.2 Portfolio Management
5.5.1.3 Diversification and Restructuring
5.5.2 Forecast for Novartis
6. US GENERICS MARKET 2011-2021
6.1 The US Generics Market Achieved 2009 Revenues of $35.6bn
6.2 Forecast for the US Generics Market, 2010-2021
6.2.1 US and China: Generics
6.3 Analysis of the US Generics Market
6.3.1 Pro-Generic Government Policies
6.3.2 Many More Blockbuster Products Will Become Susceptible to Generic Competition
6.3.3 Pricing Pressure and Regulation
6.3.4 The ANDA Backlog
6.4 Key Players in the US Generics Market
6.4.1Teva
6.4.2 Mylan
6.4.3 Sandoz
6.4.4 Hospira
6.4.5 Watson
6.5 Biosimilars
7. US OTC MARKET 2011-2021
7.1 The US OTC Market Achieved 2009 Revenues of $19.4bn
7.2 Forecast for the US OTC Market
7.3 Analysis of the US OTC Market
7.3.1 OTC Products Have Several Advantages
7.3.2 Rx-to-OTC Switching: The OTC Product Pipeline
7.3.3 Difficulties with OTC Switching
7.3.4 Sales Channels
7.4 Leading Companies in the US OTC Market
7.4.1 Johnson & Johnson
7.4.2 Procter & Gamble
7.4.3 Bayer
7.4.4 Novartis
7.4.5 Perrigo Company
8. EXPERT OPINIONS
8.1 Interview with Robert J. Easton
8.1.1 Pros and Cons of the 2010 Health Care Reform Bills
8.1.2 The Reform of Pricing
8.1.3 Different Strategies in the Industry
8.1.4 On Emerging Markets and the Loss of American Industry Leadership
8.2 Interview with Steven A. Grossman
8.2.1 On The Prospects for Health Care Reform
8.2.2 Opposition to the Reforms
8.2.3 Effects of the Bill
8.2.4 On Biosimilars Prospects
8.2.5 On FDA Regulation
8.2.6 On the Legal Challenge to the Industry
8.2.7 On FDA Funding
9. SWOT ANALYSIS OF US MARKET: CONCLUSIONS
9.1 Strengths of the US Market
9.1.1 The US Pharma Market is the Largest in the World
9.1.2 The 2010 Health Care Reforms Will Increase Coverage
9.1.3 Unmet Market Needs
9.2 Weaknesses of the US Market
9.2.1 The US Market Has Low Growth Rates
9.2.2 Margins Can Only Get Smaller
9.2.3 US Leadership and Centrality Have Decreased
9.3 Opportunities in the US Market
9.3.1 Biologicals and Biosimilars Will Grow
9.3.2 Good Prospects in Oncology
9.3.3 Opportunities in Generics and OTC Markets
9.4 Threats to the US Market
9.4.1 Opposition to Reforms
9.4.2 FDA Shortcomings
9.4.3 The Competitive Threat of China
9.5 Conclusions
LIST OF TABLES
Table 2.1, Global Pharmaceutical Market by Region, Revenues ($bn), Share of Global Market (%), 2009
Table 2.2, Top 10 Global Pharmaceutical Markets, Revenues ($bn), Share of Global Market (%), 2009
Table 2.3, Types of Employer-Funded Healthcare Provision, 2010
Table 2.4, US Government Healthcare Expenditure ($bn), 2007
Table 2.5, Provisions of the 2010 Healthcare Reforms
Table 2.6, Key Benefits and Costs to the Pharmaceutical Industry of the 2010 Health Care Reforms
Table 3.1, US Pharma Market, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 3.2, US Pharma Market and China Pharma Market, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 3.3, Sectors in the US Market, Total Revenues ($bn), Annual Growth Rate (%), Share of Market (%), 2009
Table 3.4, Top Ten Products in the CNS Sector, US Revenues ($bn), 2009
Table 3.5, CNS Sector, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 3.6, Top Ten Products in the Cardiovascular Sector, US Revenues ($bn), 2009
Table 3.7, Cardiovascular Sector, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 3.8, Top Ten Products in the Oncology Sector, US Revenues ($bn), 2009
Table 3.9, Oncology Sector, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 3.10, Top Ten Products in the Anti-infectives Sector, US Revenues ($bn), Market Share (%), 2009
Table 3.11, Anti-infectives Sector, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 3.12, Top Ten Products in the Alimentary/Metabolic Sector, US Revenues ($bn), Market Share (%), 2009
Table 3.13, Alimentary/Metabolic Sector, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 3.14, Other Sectors, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 4.1, Top 10 Products in the US Market, US Revenues ($bn), 2009
Table 4.2, Lipitor US Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 4.3, Plavix US Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 4.4, Seretide US Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 4.5, Seroquel US Revenues ($bn), US Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 4.6, Remicade US Revenues ($bn), US Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 5.1, Top Companies in the US Market, US Revenues ($bn), Total Revenues, Market Share (%), 2009
Table 5.2, Pfizer Products Approaching Patent Expiry, 2010
Table 5.3, Pfizer Pipeline, Phase III and Later, 2010
Table 5.4, Pfizer US Revenues ($bn), Global Revenues ($bn), Annual Growth (%), CAGR (%), Share of US Market (%), 2009-2021
Table 5.5, Roche Products Approaching Patent Expiry, 2010
Table 5.6, Roche Pipeline, Phase III and Later, 2010
Table 5.7, Roche US Revenues ($bn), Global Revenues ($bn), Annual Growth (%), CAGR (%), Share of US Market (%), 2009-2021
Table 5.8, AstraZeneca Products Approaching Patent Expiry, 2010
Table 5.9, AstraZeneca Pipeline, Phase III and Later, 2010
Table 5.10, AstraZeneca US Revenues ($bn), Global Revenues ($bn), Annual Growth (%), CAGR (%), Share of US Market (%), 2009-2021
Table 5.11, Merck & Co Products Approaching Patent Expiry, 2010
Table 5.12, Merck & Co Pipeline, Phase III and Later, 2010
Table 5.13, Merck & Co US Revenues ($bn), Global Revenues ($bn), Annual Growth (%), CAGR (%), Share of US Market (%), 2009-2021
Table 5.14, Novartis Products Approaching Patent Expiry, 2010
Table 5.15, Novartis Pipeline, Phase III and Later, 2010
Table 5.16, Novartis US Revenues ($bn), Global Revenues ($bn), Annual Growth (%), CAGR (%), Share of US Market (%), 2009-2021
Table 6.1, Top National Generics Markets, Revenues ($bn), Share of Global Market (%), 2009
Table 6.2, US Generic Revenues ($bn), Annual Growth (%), CAGR (%), Share of US Market (%), 2009-2021
Table 6.3, US and China Generic Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 6.4, Top Companies in the US Generics Market, 2009, Revenues ($bn), Market Share (%), 2009
Table 6.5, Teva US Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 6.6, Mylan US Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 6.7, Sandoz US Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 6.8, Hospira US Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 6.9, Watson US Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 6.10, Some Companies in the Biosimilars Market, 2010
Table 7.1, OTC Markets Worldwide, Revenues ($bn), Global Market Share (%), 2009
Table 7.2, US OTC Market, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 7.3, US and China OTC Markets, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 7.4, Top Companies in the US OTC Market, Revenues ($bn), Market Share (%), 2009
Table 7.5, Johnson & Johnson OTC Revenues ($bn), Market Share (%), CAGR (%), 2009-2021
Table 7.6, Procter & Gamble OTC Revenues ($bn), Market Share (%), CAGR (%), 2009-2021
Table 7.7, Bayer OTC Revenues ($bn), Market Share (%), CAGR (%), 2009-2021
Table 7.8, Novartis OTC Revenues ($bn), Market Share (%), CAGR (%), 2009-2021
Table 7.9, Perrigo Company OTC Revenues ($bn), Market Share (%), CAGR (%), 2009-2021
Table 2.1, Global Pharmaceutical Market by Region, Revenues ($bn), Share of Global Market (%), 2009
Table 2.2, Top 10 Global Pharmaceutical Markets, Revenues ($bn), Share of Global Market (%), 2009
Table 2.3, Types of Employer-Funded Healthcare Provision, 2010
Table 2.4, US Government Healthcare Expenditure ($bn), 2007
Table 2.5, Provisions of the 2010 Healthcare Reforms
Table 2.6, Key Benefits and Costs to the Pharmaceutical Industry of the 2010 Health Care Reforms
Table 3.1, US Pharma Market, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 3.2, US Pharma Market and China Pharma Market, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 3.3, Sectors in the US Market, Total Revenues ($bn), Annual Growth Rate (%), Share of Market (%), 2009
Table 3.4, Top Ten Products in the CNS Sector, US Revenues ($bn), 2009
Table 3.5, CNS Sector, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 3.6, Top Ten Products in the Cardiovascular Sector, US Revenues ($bn), 2009
Table 3.7, Cardiovascular Sector, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 3.8, Top Ten Products in the Oncology Sector, US Revenues ($bn), 2009
Table 3.9, Oncology Sector, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 3.10, Top Ten Products in the Anti-infectives Sector, US Revenues ($bn), Market Share (%), 2009
Table 3.11, Anti-infectives Sector, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 3.12, Top Ten Products in the Alimentary/Metabolic Sector, US Revenues ($bn), Market Share (%), 2009
Table 3.13, Alimentary/Metabolic Sector, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 3.14, Other Sectors, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 4.1, Top 10 Products in the US Market, US Revenues ($bn), 2009
Table 4.2, Lipitor US Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 4.3, Plavix US Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 4.4, Seretide US Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 4.5, Seroquel US Revenues ($bn), US Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 4.6, Remicade US Revenues ($bn), US Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 5.1, Top Companies in the US Market, US Revenues ($bn), Total Revenues, Market Share (%), 2009
Table 5.2, Pfizer Products Approaching Patent Expiry, 2010
Table 5.3, Pfizer Pipeline, Phase III and Later, 2010
Table 5.4, Pfizer US Revenues ($bn), Global Revenues ($bn), Annual Growth (%), CAGR (%), Share of US Market (%), 2009-2021
Table 5.5, Roche Products Approaching Patent Expiry, 2010
Table 5.6, Roche Pipeline, Phase III and Later, 2010
Table 5.7, Roche US Revenues ($bn), Global Revenues ($bn), Annual Growth (%), CAGR (%), Share of US Market (%), 2009-2021
Table 5.8, AstraZeneca Products Approaching Patent Expiry, 2010
Table 5.9, AstraZeneca Pipeline, Phase III and Later, 2010
Table 5.10, AstraZeneca US Revenues ($bn), Global Revenues ($bn), Annual Growth (%), CAGR (%), Share of US Market (%), 2009-2021
Table 5.11, Merck & Co Products Approaching Patent Expiry, 2010
Table 5.12, Merck & Co Pipeline, Phase III and Later, 2010
Table 5.13, Merck & Co US Revenues ($bn), Global Revenues ($bn), Annual Growth (%), CAGR (%), Share of US Market (%), 2009-2021
Table 5.14, Novartis Products Approaching Patent Expiry, 2010
Table 5.15, Novartis Pipeline, Phase III and Later, 2010
Table 5.16, Novartis US Revenues ($bn), Global Revenues ($bn), Annual Growth (%), CAGR (%), Share of US Market (%), 2009-2021
Table 6.1, Top National Generics Markets, Revenues ($bn), Share of Global Market (%), 2009
Table 6.2, US Generic Revenues ($bn), Annual Growth (%), CAGR (%), Share of US Market (%), 2009-2021
Table 6.3, US and China Generic Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 6.4, Top Companies in the US Generics Market, 2009, Revenues ($bn), Market Share (%), 2009
Table 6.5, Teva US Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 6.6, Mylan US Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 6.7, Sandoz US Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 6.8, Hospira US Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 6.9, Watson US Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 6.10, Some Companies in the Biosimilars Market, 2010
Table 7.1, OTC Markets Worldwide, Revenues ($bn), Global Market Share (%), 2009
Table 7.2, US OTC Market, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 7.3, US and China OTC Markets, Revenues ($bn), Annual Growth (%), CAGR (%), 2009-2021
Table 7.4, Top Companies in the US OTC Market, Revenues ($bn), Market Share (%), 2009
Table 7.5, Johnson & Johnson OTC Revenues ($bn), Market Share (%), CAGR (%), 2009-2021
Table 7.6, Procter & Gamble OTC Revenues ($bn), Market Share (%), CAGR (%), 2009-2021
Table 7.7, Bayer OTC Revenues ($bn), Market Share (%), CAGR (%), 2009-2021
Table 7.8, Novartis OTC Revenues ($bn), Market Share (%), CAGR (%), 2009-2021
Table 7.9, Perrigo Company OTC Revenues ($bn), Market Share (%), CAGR (%), 2009-2021
LIST OF FIGURES
Figure 2.1, Global Pharmaceutical Market by Region, Revenues ($bn), 2009
Figure 2.2, Top 10 National Pharmaceutical Markets, Revenues ($bn), 2009
Figure 2.3, US Government Health Care Expenditure ($bn), 2007
Figure 3.1, US Pharma Market, Revenues ($bn), 2009-2021
Figure 3.2, US and Chinese Pharma Markets, Revenues ($bn), 2009-2021
Figure 3.3, Sectors in the US Market, Total Revenues ($bn), 2009
Figure 3.4, Top Ten Products in the CNS Sector, US Revenues ($bn), 2009
Figure 3.5, CNS Sector, US Revenues ($bn), 2009-2021
Figure 3.6, Top Ten Products in the Cardiovascular Sector, US Revenues ($bn), 2009
Figure 3.7, Cardiovascular Sector, US Revenues ($bn), 2009-2021
Figure 3.8, Top Ten Products in the Oncology Sector, US Revenues ($bn), 2009
Figure 3.9, Oncology Sector, US Revenues ($bn), 2009-2021
Figure 3.10, Top Ten Products in the Anti-infectives Sector, US Revenues ($bn), Market Share (%), 2009
Figure 3.11, Anti-infectives Sector, US Revenues ($bn), 2009-2021
Figure 3.12, Top Ten Products in the Alimentary/Metabolic Sector, 2009
Figure 3.13, Alimentary/Metabolic Sector, Revenues ($bn), 2009-2021
Figure 4.1, Top Ten Products in the US Market, Revenues ($bn), 2009
Figure 4.2, Lipitor US Revenues ($bn), Non-US Revenues ($bn), 2009
Figure 4.3, Lipitor US Revenues ($bn), 2009-2021
Figure 4.4, Plavix US Revenues ($bn), Non-US Revenues ($bn), 2009
Figure 4.5, Plavix US Revenues ($bn), 2009-2021
Figure 4.6, Seretide US Revenues ($bn), Non-US Revenues ($bn), 2009
Figure 4.7, Seretide US Revenues ($bn), 2009-2021
Figure 4.8, Seroquel US Revenues ($bn), Non-US Revenues ($bn), 2009
Figure 4.9, Seroquel US Revenues ($bn), 2009-2021
Figure 4.10, Remicade US Revenues ($bn), Non-US Revenues ($bn), 2009
Figure 4.11, Remicade US Revenues ($bn), 2009-2021
Figure 5.1, Top Ten Companies in the US Market, Revenues ($bn), 2009
Figure 5.2, Pfizer US Revenues ($bn), Non-US Revenues ($bn), 2009
Figure 5.3, Pfizer US Revenues ($bn), Global Revenues ($bn), 2009-2021
Figure 5.4, Roche US Revenues ($bn), Non-US Revenues ($bn), 2009
Figure 5.5, Roche US Revenues ($bn), Global Revenues ($bn), 2009-2021
Figure 5.6, AstraZeneca US Revenues ($bn), Non-US Revenues ($bn), 2009
Figure 5.7, AstraZeneca US Revenues ($bn), Global Revenues ($bn), 2009-2021
Figure 5.8, Merck & Co US Revenues ($bn), Non-US Revenues ($bn), 2009
Figure 5.9, Merck & Co US Revenues ($bn), Global Revenues ($bn), 2009-2021
Figure 5.10, Merck & Co US Revenues ($bn), Non-US Revenues ($bn), 2009
Figure 5.11, Novartis US Revenues ($bn), Global Revenues ($bn), 2009-2021
Figure 6.1, US Generic Sales and Branded Product Sales ($bn), Share of Overall Market Revenues (%), 2009
Figure 6.2, US Generic and Branded Products Share of Overall Market Volume (%), 2009
Figure 6.3, US Generic and Branded Products Share of Overall Market Volume (%), 2009
Figure 6.4, US Generic Market Revenues ($bn), 2009-2021
Figure 6.5, US and China Generic Market Revenues ($bn), 2009-2021
Figure 6.6, Top Companies in the US Generics Market, 2009, Revenues ($bn), 2009
Figure 6.7, Teva US Revenues ($bn), 2009-2021
Figure 6.8, Mylan US Revenues ($bn), 2009-2021
Figure 6.9, Sandoz US Revenues ($bn), 2009-2021
Figure 6.10, Hospira US Revenues ($bn), 2009-2021
Figure 6.11, Watson US Revenues ($bn), 2009-2021
Figure 7.1, US OTC and Rx Revenues ($bn), 2009
Figure 7.2, OTC Markets Worldwide, Revenues ($bn), 2009
Figure 7.3, US OTC Market, Revenues ($bn), 2009-2021
Figure 7.4, US and China OTC Markets, Revenues ($bn), 2009-2021
Figure 7.5, Top Companies in the US OTC Market, Revenues ($bn), 2009
Figure 7.6, Johnson & Johnson OTC Revenues ($bn), 2009-2021
Figure 7.7, Procter & Gamble OTC Revenues ($bn), 2009-2021
Figure 7.8, Bayer OTC Revenues ($bn), 2009-2021
Figure 7.9, Novartis OTC Revenues ($bn), 2009-2021
Figure 7.10, Perrigo Company OTC Revenues ($bn), 2009-2021а
COMPANIES LISTED
Abbott
Abraxis
Accord Healthcare
Adimab
Alcon
Almirall
American Consumer Products
Amerisource Bergen
Amgen
Andrx
Antisoma
Apotex
Arakis
Ariad
Arrow
Asian Cancer Research Group
Astellas
AstraZeneca
Bayer
Beijing University
BioCon
Bioniche Pharma
Biovail Laboratories
Bristol-Myers Squibb
Cardinal Health
Cardiome
Celera
Celgene
Celldex
Center for Drug Evaluation and Research (CDER)
Centocor Ortho Biotech
Chiron
Chugai
Cleveland Clinic
Cobalt
Coley Pharmaceuticals
Corthera Inc
Cougar Biotechnology
CovX
Crucell Biotechnology
Cumencor
CVS Pharmacy
Data and Safety Monitoring Board
Depomed
Dey Pharma
Diabact
Dollar Central
Dr. Reddy's Laboratories
Eli Lilly
Emisphere
Encysive Pharmaceuticals
Eon Labs
Facet Biotech
Food and Drug Administration (FDA)
Forest
Fujisawa
Gedeon Richter
Genentech
Genpharm
Gilead Sciences
GlaxoSmithKline
Gloucester Pharmaceuticals
Grifols
Guangdong Province People's Hospital
Handa Pharmaceuticals
Health Mart
Hexal AG
Hospira
HPS Group LLC
Independent Payment Advisory Board
Incyte
Ipsen
Itero
Ivax
Janssen Pharmaceutica
Johnson & Johnson
Kern Pharma
King
Kowa
Leiner Health Products
Laboratorios Alter
Laboratorios Belac
Laboratorios Cinfa
Lonza
Malinckdrodt
Matrix Laboratories
McKesson
Mayo
MedImmune
Medivation
Menarini
Merck & Co
Merck KGaA
Merck Banyu
MicuRx
Millipore
Mitsubishi Tanabe
Mylan
Mylan Dura GmbH
National Children's Medical Center (Japan)
Nektar Therapeutics
Neolab
NeuTec
Nordic Bioscience
Novartis
NutraMax Products
Novo Nordisk
The Office of Surveillance and Epidemiology (OSE)
Organization for Economic Co-operation and Development (OECD)
Orexo
Orion Laboratories
OSI
Otsuka
Paratek
Par Pharma
Peking Union Medical College Hospital
Perrigo Company
Pharmaceutical Research and Manufacturers of America (PhRMA)
Pharmascience
Pfizer
Pfizer Greenstone
Pierre Fabre
PlaNrt Finance
Plexxikon
PowderMed
Procter and Gamble
Protalix
Protez
Purdue
Ratiopharm
Reckett Benckiser
Roche
Sagmel
Scisive Consulting
Sandoz
Sanofi-Aventis
Schering-Plough
Schwarz
Seattle Genetics
SeBo
Serenex
Shanghai Kiao Tong University
Sosei
Speedel
Taito
Talecris
Targacept
Targegen
Target
Teva
Toho University
Topsun Science and Technology Co
University Hospital Beijing
Upjohn
US Centers for Disease Control & Prevention (CDC)
US Congress
US Department of Health and Human Services
US National Institutes of Health (NIH)
Vectura
Vertex Pharmaceuticals
Viiv Healthcare
Viriom
Walgreens
Wal-Mart
Watson
World Health Organization (WHO)
Wuhan National Bioindustry Base Construction
WuXi Pharmatech
Wyeth
Xoma
Yoshitomi
Zhangjiang Hi-Tech Park
Zhejiang Tianyuanа
Figure 2.1, Global Pharmaceutical Market by Region, Revenues ($bn), 2009
Figure 2.2, Top 10 National Pharmaceutical Markets, Revenues ($bn), 2009
Figure 2.3, US Government Health Care Expenditure ($bn), 2007
Figure 3.1, US Pharma Market, Revenues ($bn), 2009-2021
Figure 3.2, US and Chinese Pharma Markets, Revenues ($bn), 2009-2021
Figure 3.3, Sectors in the US Market, Total Revenues ($bn), 2009
Figure 3.4, Top Ten Products in the CNS Sector, US Revenues ($bn), 2009
Figure 3.5, CNS Sector, US Revenues ($bn), 2009-2021
Figure 3.6, Top Ten Products in the Cardiovascular Sector, US Revenues ($bn), 2009
Figure 3.7, Cardiovascular Sector, US Revenues ($bn), 2009-2021
Figure 3.8, Top Ten Products in the Oncology Sector, US Revenues ($bn), 2009
Figure 3.9, Oncology Sector, US Revenues ($bn), 2009-2021
Figure 3.10, Top Ten Products in the Anti-infectives Sector, US Revenues ($bn), Market Share (%), 2009
Figure 3.11, Anti-infectives Sector, US Revenues ($bn), 2009-2021
Figure 3.12, Top Ten Products in the Alimentary/Metabolic Sector, 2009
Figure 3.13, Alimentary/Metabolic Sector, Revenues ($bn), 2009-2021
Figure 4.1, Top Ten Products in the US Market, Revenues ($bn), 2009
Figure 4.2, Lipitor US Revenues ($bn), Non-US Revenues ($bn), 2009
Figure 4.3, Lipitor US Revenues ($bn), 2009-2021
Figure 4.4, Plavix US Revenues ($bn), Non-US Revenues ($bn), 2009
Figure 4.5, Plavix US Revenues ($bn), 2009-2021
Figure 4.6, Seretide US Revenues ($bn), Non-US Revenues ($bn), 2009
Figure 4.7, Seretide US Revenues ($bn), 2009-2021
Figure 4.8, Seroquel US Revenues ($bn), Non-US Revenues ($bn), 2009
Figure 4.9, Seroquel US Revenues ($bn), 2009-2021
Figure 4.10, Remicade US Revenues ($bn), Non-US Revenues ($bn), 2009
Figure 4.11, Remicade US Revenues ($bn), 2009-2021
Figure 5.1, Top Ten Companies in the US Market, Revenues ($bn), 2009
Figure 5.2, Pfizer US Revenues ($bn), Non-US Revenues ($bn), 2009
Figure 5.3, Pfizer US Revenues ($bn), Global Revenues ($bn), 2009-2021
Figure 5.4, Roche US Revenues ($bn), Non-US Revenues ($bn), 2009
Figure 5.5, Roche US Revenues ($bn), Global Revenues ($bn), 2009-2021
Figure 5.6, AstraZeneca US Revenues ($bn), Non-US Revenues ($bn), 2009
Figure 5.7, AstraZeneca US Revenues ($bn), Global Revenues ($bn), 2009-2021
Figure 5.8, Merck & Co US Revenues ($bn), Non-US Revenues ($bn), 2009
Figure 5.9, Merck & Co US Revenues ($bn), Global Revenues ($bn), 2009-2021
Figure 5.10, Merck & Co US Revenues ($bn), Non-US Revenues ($bn), 2009
Figure 5.11, Novartis US Revenues ($bn), Global Revenues ($bn), 2009-2021
Figure 6.1, US Generic Sales and Branded Product Sales ($bn), Share of Overall Market Revenues (%), 2009
Figure 6.2, US Generic and Branded Products Share of Overall Market Volume (%), 2009
Figure 6.3, US Generic and Branded Products Share of Overall Market Volume (%), 2009
Figure 6.4, US Generic Market Revenues ($bn), 2009-2021
Figure 6.5, US and China Generic Market Revenues ($bn), 2009-2021
Figure 6.6, Top Companies in the US Generics Market, 2009, Revenues ($bn), 2009
Figure 6.7, Teva US Revenues ($bn), 2009-2021
Figure 6.8, Mylan US Revenues ($bn), 2009-2021
Figure 6.9, Sandoz US Revenues ($bn), 2009-2021
Figure 6.10, Hospira US Revenues ($bn), 2009-2021
Figure 6.11, Watson US Revenues ($bn), 2009-2021
Figure 7.1, US OTC and Rx Revenues ($bn), 2009
Figure 7.2, OTC Markets Worldwide, Revenues ($bn), 2009
Figure 7.3, US OTC Market, Revenues ($bn), 2009-2021
Figure 7.4, US and China OTC Markets, Revenues ($bn), 2009-2021
Figure 7.5, Top Companies in the US OTC Market, Revenues ($bn), 2009
Figure 7.6, Johnson & Johnson OTC Revenues ($bn), 2009-2021
Figure 7.7, Procter & Gamble OTC Revenues ($bn), 2009-2021
Figure 7.8, Bayer OTC Revenues ($bn), 2009-2021
Figure 7.9, Novartis OTC Revenues ($bn), 2009-2021
Figure 7.10, Perrigo Company OTC Revenues ($bn), 2009-2021а
COMPANIES LISTED
Abbott
Abraxis
Accord Healthcare
Adimab
Alcon
Almirall
American Consumer Products
Amerisource Bergen
Amgen
Andrx
Antisoma
Apotex
Arakis
Ariad
Arrow
Asian Cancer Research Group
Astellas
AstraZeneca
Bayer
Beijing University
BioCon
Bioniche Pharma
Biovail Laboratories
Bristol-Myers Squibb
Cardinal Health
Cardiome
Celera
Celgene
Celldex
Center for Drug Evaluation and Research (CDER)
Centocor Ortho Biotech
Chiron
Chugai
Cleveland Clinic
Cobalt
Coley Pharmaceuticals
Corthera Inc
Cougar Biotechnology
CovX
Crucell Biotechnology
Cumencor
CVS Pharmacy
Data and Safety Monitoring Board
Depomed
Dey Pharma
Diabact
Dollar Central
Dr. Reddy's Laboratories
Eli Lilly
Emisphere
Encysive Pharmaceuticals
Eon Labs
Facet Biotech
Food and Drug Administration (FDA)
Forest
Fujisawa
Gedeon Richter
Genentech
Genpharm
Gilead Sciences
GlaxoSmithKline
Gloucester Pharmaceuticals
Grifols
Guangdong Province People's Hospital
Handa Pharmaceuticals
Health Mart
Hexal AG
Hospira
HPS Group LLC
Independent Payment Advisory Board
Incyte
Ipsen
Itero
Ivax
Janssen Pharmaceutica
Johnson & Johnson
Kern Pharma
King
Kowa
Leiner Health Products
Laboratorios Alter
Laboratorios Belac
Laboratorios Cinfa
Lonza
Malinckdrodt
Matrix Laboratories
McKesson
Mayo
MedImmune
Medivation
Menarini
Merck & Co
Merck KGaA
Merck Banyu
MicuRx
Millipore
Mitsubishi Tanabe
Mylan
Mylan Dura GmbH
National Children's Medical Center (Japan)
Nektar Therapeutics
Neolab
NeuTec
Nordic Bioscience
Novartis
NutraMax Products
Novo Nordisk
The Office of Surveillance and Epidemiology (OSE)
Organization for Economic Co-operation and Development (OECD)
Orexo
Orion Laboratories
OSI
Otsuka
Paratek
Par Pharma
Peking Union Medical College Hospital
Perrigo Company
Pharmaceutical Research and Manufacturers of America (PhRMA)
Pharmascience
Pfizer
Pfizer Greenstone
Pierre Fabre
PlaNrt Finance
Plexxikon
PowderMed
Procter and Gamble
Protalix
Protez
Purdue
Ratiopharm
Reckett Benckiser
Roche
Sagmel
Scisive Consulting
Sandoz
Sanofi-Aventis
Schering-Plough
Schwarz
Seattle Genetics
SeBo
Serenex
Shanghai Kiao Tong University
Sosei
Speedel
Taito
Talecris
Targacept
Targegen
Target
Teva
Toho University
Topsun Science and Technology Co
University Hospital Beijing
Upjohn
US Centers for Disease Control & Prevention (CDC)
US Congress
US Department of Health and Human Services
US National Institutes of Health (NIH)
Vectura
Vertex Pharmaceuticals
Viiv Healthcare
Viriom
Walgreens
Wal-Mart
Watson
World Health Organization (WHO)
Wuhan National Bioindustry Base Construction
WuXi Pharmatech
Wyeth
Xoma
Yoshitomi
Zhangjiang Hi-Tech Park
Zhejiang Tianyuanа
